Monthly Archives: September 2016

What is a Pseudoenzyme, and why?

pseudoenzymes-blog-image-3

The latest research in the pseudoenzyme field was presented at what claimed to be the world’s first dedicated pseudoenzyme conference in Liverpool earlier this month, with the ways in which they function and evolve among the topics discussed.

Peer review: opting out

Print

Disgusted with current peer review processes, some are opting out of peer review altogether and publishing on preprint servers. Can we offer a less radical solution?

Heroes of peer review: Hyongbum (Henry) Kim

Peer reviewers are the unsung heroes of science. We celebrate reviewers through a series of interviews with people who have made particularly strong recent contributions to Genome Biology as reviewers. The first interview is with Hyongbum (Henry) Kim, an Associate Professor at Yonsei University College of Medicine in South Korea.

Urine: an untapped resource for human disease modeling

muscle

The genetic diversity of muscle diseases is extensive, and new tools are required to investigate the mechanisms of disease and test new therapeutic interventions.  Cells isolated from patients serve as a source for specific models that allow for the study of disease in the context of the patient’s own genetic landscape, and these cellular models are taking on increasing importance.

The future of epigenetic drugs

pills

In the light of increasing knowledge on the role epigenetic factors play in disease, it is now becoming apparent that epigenetics could be ideal therapeutic targets – particularly taking into consideration that many of these epigenetic factors are reversible. Epigenetic drugs are incredibly potent and can help reverse abnormal gene expression that can result in various diseases.